138 related articles for article (PubMed ID: 8739853)
1. Serum procollagen type III peptide in chronic hepatitis B. Relationship to disease activity and response to interferon-alpha therapy.
Giustina G; Fattovich G; De Paoli M; Guido M; Favarato S; Rugge M; Alberti A; Ruol A; Plebani M
Int J Clin Lab Res; 1996; 26(1):33-6. PubMed ID: 8739853
[TBL] [Abstract][Full Text] [Related]
2. Liver stellate cells and aminoterminal peptide of type III procollagen in chronic hepatitis C treated with interferon.
Gabrielli GB; Casaril M; Stanzial AM; Colombari R; Pasino M; Corrocher R
Hepatogastroenterology; 2003; 50(54):2017-21. PubMed ID: 14696456
[TBL] [Abstract][Full Text] [Related]
3. Interferon-alpha 2a increases serum concentration of hyaluronic acid and type III procollagen aminoterminal propeptide in patients with chronic hepatitis B virus infection.
Zöhrens G; Armbrust T; Meyer Zum Büschenfelde KH; Ramadori G
Dig Dis Sci; 1994 Sep; 39(9):2007-13. PubMed ID: 8082511
[TBL] [Abstract][Full Text] [Related]
4. Alpha-interferon improves liver fibrosis in chronic hepatitis C: clinical significance of the serum N-terminal propeptide of procollagen type III.
Serejo F; Costa A; Oliveira AG; Ramalho F; Batista A; De Moura MC
Dig Dis Sci; 2001 Aug; 46(8):1684-9. PubMed ID: 11508668
[TBL] [Abstract][Full Text] [Related]
5. Decrease in serum levels of markers of hepatic connective tissue turnover during and after treatment of chronic hepatitis B with interferon-alpha.
Teran JC; Mullen KD; Hoofnagle JH; McCullough AJ
Hepatology; 1994 Apr; 19(4):849-56. PubMed ID: 8138256
[TBL] [Abstract][Full Text] [Related]
6. Changes in serum tissue inhibitor of matrix metalloproteinase-1 after interferon alpha treatment in chronic hepatitis C.
Mitsuda A; Suou T; Ikuta Y; Kawasaki H
J Hepatol; 2000 Apr; 32(4):666-72. PubMed ID: 10782917
[TBL] [Abstract][Full Text] [Related]
7. Long-term variations of serum laminin and procollagen III peptide in chronic HCV hepatitis after alpha-interferon therapy.
Casaril M; Capra F; Gabrielli GB; Tognella P; Rizzi A; Squarzoni S; De Maria E; Colombari R; De Sandre G; Corrocher R
Ital J Gastroenterol; 1996 Jan; 28(1):15-9. PubMed ID: 8743068
[TBL] [Abstract][Full Text] [Related]
8. Fibrogenesis serum markers in patients with chronic hepatitis C treated with alpha-IFN.
Fabris P; Marranconi F; Bozzola L; Biasin MR; De Lazzari F; Plebani M; Benedetti P; Tositti G; Pellizzer G; Stecca C; de Lalla F
J Gastroenterol; 1999 Jun; 34(3):345-50. PubMed ID: 10433010
[TBL] [Abstract][Full Text] [Related]
9. Serum markers of hepatic fibrogenesis in chronic hepatitis type C treated with alfa-2A interferon.
Gallorini A; Plebani M; Pontisso P; Chemello L; Masiero M; Mantovani G; Alberti A
Liver; 1994 Oct; 14(5):257-64. PubMed ID: 7997085
[TBL] [Abstract][Full Text] [Related]
10. Changes in histological lesions and serum fibrogenesis markers in chronic hepatitis C patients non-responders to interferon alpha.
Leroy V; De Traversay C; Barnoud R; Hartmann JD; Baud M; Ouzan D; Zarski JP
J Hepatol; 2001 Jul; 35(1):120-6. PubMed ID: 11495029
[TBL] [Abstract][Full Text] [Related]
11. Changes of liver fibrosis in chronic hepatitis C patients with no response to interferon-alpha therapy: including quantitative assessment by a morphometric method.
Yagura M; Murai S; Kojima H; Tokita H; Kamitsukasa H; Harada H
J Gastroenterol; 2000; 35(2):105-11. PubMed ID: 10680665
[TBL] [Abstract][Full Text] [Related]
12. Long-term decrease in serum N-terminal propeptide of type III procollagen in patients with chronic hepatitis C treated with interferon alfa.
Suou T; Hosho K; Kishimoto Y; Horie Y; Kawasaki H
Hepatology; 1995 Aug; 22(2):426-31. PubMed ID: 7635409
[TBL] [Abstract][Full Text] [Related]
13. alpha-Interferon in the treatment of chronic viral hepatitis: effects on fibrogenesis serum markers.
Capra F; Casaril M; Gabrielli GB; Tognella P; Rizzi A; Dolci L; Colombari R; Mezzelani P; Corrocher R; De Sandre G
J Hepatol; 1993 Apr; 18(1):112-8. PubMed ID: 8340603
[TBL] [Abstract][Full Text] [Related]
14. Serum type I collagen and N-terminal peptide of type III procollagen in chronic hepatitis. Relationship to liver histology and conventional liver tests.
Trinchet JC; Hartmann DJ; Pateron D; Laarif M; Callard P; Ville G; Beaugrand M
J Hepatol; 1991 Mar; 12(2):139-44. PubMed ID: 1711064
[TBL] [Abstract][Full Text] [Related]
15. Serum carboxy terminal propeptide of type I procollagen to amino terminal propeptide of type III procollagen ratio is a better indicator than each single propeptide and 7S domain type IV collagen for progressive fibrogenesis in chronic viral liver diseases.
Lin DY; Chu CM; Sheen IS; Liaw YF
Dig Dis Sci; 1995 Jan; 40(1):21-7. PubMed ID: 7821112
[TBL] [Abstract][Full Text] [Related]
16. Oxidative stress in chronic hepatitis C: the effect of interferon therapy and correlation with pathological features.
Serejo F; Emerit I; Filipe PM; Fernandes AC; Costa MA; Freitas JP; de Moura MC
Can J Gastroenterol; 2003 Nov; 17(11):644-50. PubMed ID: 14631465
[TBL] [Abstract][Full Text] [Related]
17. Resistance to alpha interferon therapy in HCV chronic liver disease: role of hepatic fibrosis.
Di Costanzo GG; Ascione A; Lanza AG; De Luca M; Bracco A; Lojodice D; Marsilia GM; Ferbo U
Ital J Gastroenterol; 1996 Apr; 28(3):140-6. PubMed ID: 8789824
[TBL] [Abstract][Full Text] [Related]
18. Serum hyaluronic acid reflects the effect of interferon treatment on hepatic fibrosis in patients with chronic hepatitis C.
Yamada M; Fukuda Y; Koyama Y; Nakano I; Urano F; Katano Y; Hayakawa T
J Gastroenterol Hepatol; 1996 Jul; 11(7):646-51. PubMed ID: 8840240
[TBL] [Abstract][Full Text] [Related]
19. [Serum variations of 2 markers of fibrogenesis in chronic hepatitis C treated with alpha interferon].
Soresi M; Bascone F; Agate V; Carroccio A; Barresi E; Cartabellotta A; Aragona F; Montalto G
Recenti Prog Med; 1997 Feb; 88(2):73-6. PubMed ID: 9148370
[TBL] [Abstract][Full Text] [Related]
20. Relationship between procollagen III aminoterminal propeptide and hyaluronan serum levels and histological fibrosis in primary biliary cirrhosis and chronic viral hepatitis C.
Guéchot J; Poupon RE; Giral P; Balkau B; Giboudeau J; Poupon R
J Hepatol; 1994 Mar; 20(3):388-93. PubMed ID: 8014451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]